

February 27, 2019



Endonovo Therapeutics Announces New Website Launch

The completely redesigned website offers visitors deeper insight into the Company's core product, SofPulse®

LOS ANGELES, CA, Feb. 27, 2019 (GLOBE NEWSWIRE) -- [Endonovo Therapeutics, Inc.](http://www.endonovotherapeutics.com) (OTCQB: ENDV) ("Endonovo" or the "Company"), a commercial-stage developer of non-invasive Electroceutical™ therapeutic devices, announced today the launch of its newly revamped website www.sofpulse.com.

The website's redesign has significantly improved functionality and enriched content focused on SofPulse®, Endonovo's flagship product. SofPulse® is an easy-to-place, non-invasive device that delivering targeted Pulsed Electromagnetic Frequencies (tPEMF) to enhance post-surgical recovery, naturally. This innovative process utilizes proprietary technology to reduce pain, swelling and inflammation. The therapy is non-invasive and non-pharmacologic, with no known side effects and no potential for overdose or dependency. SofPulse® has been used effectively and studied extensively in soft tissue postoperative management.

In addition to the upgraded SofPulse.com web site, Endonovo Therapeutics is proud to announce the release of our brand new 90 second "SofPulse® Solution" video. This short video provides viewers an up close and personal look at what SofPulse® is, what it does, how it works and how it provides groundbreaking benefits to patients and Physician's alike. The video can be viewed on the home page.

"We are excited about our new website launch and the robust information it provides for patients, clinicians, medical community, partners and media to better understand SofPulse®," said Alan Collier, Endonovo's Chief Executive Officer. "Our newly designed site will allow our visitors to have a thoroughly informative experience and introduces the SofPulse® Solution via our 90 second video.

About Endonovo Therapeutics

Endonovo Therapeutics, Inc. is a commercial-stage developer of non-invasive wearable Electroceuticals™ therapeutic devices. The Company's current portfolio of commercial and clinical-stage wearable Electroceuticals™ therapeutic devices addresses wound healing, pain, post-surgical pain and edema, cardiovascular disease, chronic kidney disease, and Central Nervous System (CNS) Disorders, including traumatic brain injury (TBI), acute concussions, post-concussion syndrome and multiple sclerosis. The Company's non-invasive Electroceutical™ therapeutic device, SofPulse®, using pulsed short-wave radiofrequency at 27.12 MHz has been FDA-Cleared and CE Marked for the palliative treatment of soft tissue injuries and post-operative pain and edema, and has CMS National Coverage for the treatment of chronic wounds. The Company's current portfolio of pre-

clinical stage Electroceuticals™ therapeutic devices address chronic kidney disease, liver disease non-alcoholic steatohepatitis (NASH), cardiovascular and peripheral artery disease (PAD), and ischemic stroke. The Company's non-invasive, wearable Electroceuticals™ therapeutic devices work by restoring key electrochemical processes that initiate anti-inflammatory and growth factor cascades necessary for healing to occur. www.endonovo.com

Safe Harbor Statement

This press release contains information that constitutes forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements, trends, analysis, and other information contained in this press release including words such as "anticipate," "believe," "plan," "estimate," "expect," "intend," and other similar expressions of opinion, constitute forward-looking statements. Any such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from any future results described within the forward-looking statements. Risk factors that could contribute to such differences include those matters more fully disclosed in the Company's reports filed with the Securities and Exchange Commission. The forward-looking information provided herein represents the Company's estimates as of the date of the press release, and subsequent events and developments may cause the Company's estimates to change. The Company specifically disclaims any obligation to update the forward-looking information in the future. Therefore, this forward-looking information should not be relied upon as representing the Company's estimates of its future financial performance as of any date subsequent to the date of this press release.

Investor Relations Contact:

Endonovo Therapeutics, Inc.
Mr. Andrew Barwicki
516-662-9461
Andrew@barwicki.com
www.endonovo.com



Source: Endonovo Therapeutics, Inc.